GenScript Biotech Corporation (GENSCRIPT) financials
HKSE · Healthcare · Biotechnology · 6,135 employees · CEO Weihui Shao
- Price
- $3.54 0.0%
- Market cap
- $7.97B
- Enterprise value
- $8B Data as of 2026-11-21
- Last report
- Q2 '26 filed 2026-06-30
- Next report
- 2027-03-24
Valuation & key figures
- Market cap
- $7.97B Updated 11m ago
- Revenue
- $844M Trailing 12 months
- Revenue growth
- -7% FY2026 consensus
- Profit margin
- -75.4% Net income / revenue, TTM
- P/E
- No P/E Loss in the last twelve months
- P/S
- 9.4× Price / sales, TTM
- EV / EBITDA
- 39.0× TTM
- Free cash flow
- $50.3M Trailing 12 months
- Net income
- -$636M Trailing 12 months
- Revenue estimate
- $894M FY2026 consensus
- Earnings
- 2027-03-24 Revenue est. $496M · Updated 11m ago
- Dividend
- HK$0.01 Per payment · 2017-06-05
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Revenue growth slowing: -22.3% year on yearQ2 '26 revenue $403M, against an average of 16.6% over the four half-years before.
- Operating margin 14.9% (TTM), -6.8 pp on a year agoOperating income grew -30.0% while revenue grew 1.9%.
- Capex 11.8% of revenue (a year ago 3.9%)$99.3M invested in the last 2 half-years (+209.1% on a year earlier). Free cash flow $50.3M.
- Returned $225M to shareholders = 447.6% of free cash flowBuybacks $225M (a year earlier $0), dividends $0, stock-based pay $5.22M (TTM). More than the free cash flow: paid from cash or debt.
- Diluted share count up 1.4% in a year2.19B diluted shares in Q2 '26, 2.16B a year earlier.
- Net cash $577MCash + short-term investments $831M, debt incl. leases $255M; a year ago net debt $151M.
Last quarter: Q2 '26
Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q2 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $403M | $519M | -22.3% |
| Gross margin | 51.1% | 61.8% | -10.7 pp |
| Operating income | $49.4M | $179M | -72.4% |
| Operating margin | 12.3% | 34.5% | -22.3 pp |
| Net income | -$129M | -$25.5M | -406.8% |
| Diluted EPS | -$0.06 | -$0.02 | -171.3% |
| Operating cash flow | $56.7M | $233M | -75.6% |
| Capex | $47.6M | $32.1M | +48.1% |
| Free cash flow | $9.1M | $200M | -95.5% |
| R&D | $39.3M | $31.3M | +25.6% |
| Stock-based compensation | $0 | $9.58M | -100.0% |
Revenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyMargins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 2 half-years
cash flow statement- Operating cash flow
- $150M
- Capex
- -$99.3M
- Buybacks
- -$225M
- Dividends
- $0
- Acquisitions
- -$8.32M
- Net debt issued
- $78M
- Stock-based compensation
- $5.22M
- Free cash flow
- $50.3M
- Returned to shareholders / FCF
- 447.6%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | – | 12.7× 1 of 5 years | 12.7× – 12.7× |
| EV / EBITDA | 39.0× | 31.4× 3 of 5 years | 10.8× – 43.2× |
| EV / Sales | 9.5× | 8.6× | 3.7× – 16.2× |
| Price / FCF | 158.4× | 14.3× 1 of 5 years | 14.3× – 14.3× |
| Price / Book | 2.0× | 4.1× | 0.6× – 8.6× |
| FCF yield | 0.6% | -2.4% | -8.3% – 7.0% |
| Return on invested capital | 2.9% | -7.4% | -22.5% – 5.5% |
| Return on equity | -16.2% | -1.7% | -34.3% – 68.5% |
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $894M | -6.8% | $0.01 | +105.2% | – | 3 |
| FY2027 | $1.2B | +34.1% | $0.09 | +622.4% | – | 3 |
| FY2028 | $1.52B | +26.5% | $0.17 | +76.2% | – | 4 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-21